

Initiator Pharma A/S: Publication of prospectus

Initiator Pharma A/S ("Initiator Pharma") hereby publishes prospectus concerning the rights issue of units starting on March 15th, 2018. The prospectus is available via the company's (www.initiatorpharma.com), AktieTorget's (www.aktietorget.se) and Sedermera Fondkommission's (www.sedermera.se) respective websites. Teaser and subscription form without subscription rights will be published in connection with the start of the subscription period.

Prospectus, teaser and subscription form

Prospectus for the rights issue is now published on Initiator Pharma's, Sedermera Fondkommission's and AktieTorget's respective websites (www.initiatorpharma.com, www.sedermera.se och www.aktietorget.se). Teaser and subscription form without subscription rights will be published in connection with the start of the subscription period.

Investor meetings

In connection with the rights issue, representatives for Initiator Pharma will participate at investor meetings to inform about the company and its future plans. Participation at the investor meetings is free and food and drinks will be offered. For more information about the investor meetings, please visit Sedermera Fondkommission's website (www.sedermera.se) or contact Sedermera Fondkommission on 040-615 14 10, or event@sedermerna.se.

Financial advisor

Sedermera Fondkommission is the financial advisor to Initiator Pharma in connection with the rights issue.

For further information about the planned unit issue, please contact:

Sedermera Fondkommission
Telephone: +46 40-615 14 10
E-mail: info@sedermerna.se

For further information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for patient suffering from Erectile Dysfunction (ED) and will improve the quality of life for the growing number for patients (and their partners) that do not respond to the current market PDE5i medications. Learn more at initiatorpharma.com.

About erectile dysfunction

Erectile dysfunction is characterized by the inability to develop or maintain an erection of the penis during sexual activity. ED affects more than 150 million men worldwide and that number is expected to increase to more than 320 million by 2025, fuelled by aging demographics and increasing prevalence of life style diseases such as diabetes. The large diabetic ED patient segment is often responding poorly to the current medication and is therefore of particular interest for Initiator Pharma. ED patients have decreased quality of life due to various psychosocial factors such as low self-esteem, depression, sadness, anger, frustration, anxiety, relationship problems etc. (Althof, 2002; Shabsigh et al., 1998, Tsai, 2008; Litwin et al., 1998).

This is an English translation of a press release originally drafted in Swedish. In the case of any discrepancies, the Swedish version shall prevail.